Glycogen synthase kinase-3β: Variation over time and the possible association with mood and cognition in healthy individuals

Neuropsychobiology

Volumn 73, Issue 2, 2016, Pages 108-115

  Munkholm, Klaus ^a   Lenskjold, Toke ^a   Jacoby, Anne Sophie ^a   Miskowiak, Kamilla Woznica ^a   Vinberg, Maj ^a   Joaquim, Helena Giroud Passarelli ^c   Talib, Leda Leme ^c   Gattaz, Wagner Farid ^c   Kessing, Lars Vedel ^a,b  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Biomarker; Bipolar disorder; Peripheral blood

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA; CYTOSKELETON PROTEIN; NIN PROTEIN, HUMAN; NUCLEAR PROTEIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COGNITION; ENZYME ACTIVITY; FEMALE; FOLLOW UP; HUMAN; MALE; MENTAL INSTABILITY; MOOD; MOOD CHANGE; NEUROPSYCHOLOGICAL TEST; PATHOPHYSIOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SEASON; SPRING; SUMMER; ADOLESCENT; AFFECT; BLOOD; BLOOD ANALYSIS; ENZYME IMMUNOASSAY; LONGITUDINAL STUDY; MIDDLE AGED; PHOSPHORYLATION; PHYSIOLOGY; TIME FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; AFFECT; BLOOD CHEMICAL ANALYSIS; COGNITION; CYTOSKELETAL PROTEINS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; NUCLEAR PROTEINS; PHOSPHORYLATION; SEASONS; TIME FACTORS; YOUNG ADULT;

EID: 84961393803     PISSN: 0302282X     EISSN: 14230224     Source Type: Journal    
DOI: 10.1159/000444489     Document Type: Article

References (58)

1. Geddes JR, Goodwin GM, Rendell J, Azorin JM, Cipriani A, Ostacher MJ, Morriss R, Alder N, Juszczak E. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 2010; 375: 385-395
2. Kessing LV, Hellmund G, Geddes JR, Goodwin GM, Andersen PK. Valproate v. lithium in the treatment of bipolar disorder in clinical practice: observational nationwide register-based cohort study. Br J Psychiatry 2011; 199: 57-63
3. Petersen ML, Sinisi SE, Van Der Laan MJ. Estimation of direct causal effects. Epidemiology 2006; 17: 276-284
4. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 1996; 93: 8455-8459
5. Stambolic V, Ruel L, Woodgett JR. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 1996; 6: 1664-1668
6. Woodgett JR. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J 1990; 9: 2431-2438
7. Ryves WJ, Harwood AJ. Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem Biophys Res Commun 2001; 280: 720-725
8. Jope RS, Yuskaitis CJ, Beurel E. Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res 2007; 32: 577-595
9. Bazinet RP, Rao JS, Chang L, Rapoport SI, Lee HJ. Chronic carbamazepine decreases the incorporation rate and turnover of arachidonic acid but not docosahexaenoic acid in brain phospholipids of the unanesthetized rat: relevance to bipolar disorder. Biol Psychiatry 2006; 59: 401-407
10. Peineau S, Bradley C, Taghibiglou C, Doherty A, Bortolotto ZA, Wang YT, Collingridge GL. The role of GSK-3 in synaptic plasticity. Br J Pharmacol 2008; 153(suppl 1): S428-S437
11. Martin M, Rehani K, Jope RS, Michalek SM. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol 2005; 6: 777-784
12. Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M, Yucel M, Gama CS, Dodd S, Dean B, Magalhaes PV, Amminger P, McGorry P, Malhi GS. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 2011; 35: 804-817
13. Kapczinski F, Vieta E, Andreazza AC, Frey BN, Gomes FA, Tramontina J, Kauer-Santanna M, Grassi-Oliveira R, Post RM. Allostatic load in bipolar disorder: implications for pathophysiology and treatment. Neurosci Biobehav Rev 2008; 32: 675-692
14. Leonard B, Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 2012; 36: 764-785
15. King MK, Pardo M, Cheng Y, Downey K, Jope RS, Beurel E. Glycogen synthase kinase-3 inhibitors: rescuers of cognitive impairments. Pharmacol Ther 2014; 141: 1-12
16. Torres IJ, Boudreau VG, Yatham LN. Neuropsychological functioning in euthymic bipolar disorder: a meta-Analysis. Acta Psychiatr Scand Suppl 2007; 434: 17-26
17. Kessing LV, Andersen PK. Does the risk of developing dementia increase with the number of episodes in patients with depressive disorder and in patients with bipolar disorder? J Neurol Neurosurg Psychiatry 2004; 75: 1662-1666
18. Kessing LV, Olsen EW, Mortensen PB, Andersen PK. Dementia in affective disorder: a case-register study. Acta Psychiatr Scand 1999; 100: 176-185
19. Kessing LV, Forman JL, Andersen PK. Does lithium protect against dementia?. Bipolar Disord 2010; 12: 87-94
20. Kessing LV, Sondergard L, Forman JL, Andersen PK. Lithium treatment and risk of dementia. Arch Gen Psychiatry 2008; 65: 1331-1335
21. Nunes PV, Forlenza OV, Gattaz WF. Lithium and risk for Alzheimers disease in elderly patients with bipolar disorder. Br J Psychiatry 2007; 190: 359-360
22. Forlenza OV, Diniz BS, Radanovic M, Santos FS, Talib LL, Gattaz WF. Disease-modifying properties of long-Term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br J Psychiatry 2011; 198: 351-356
23. Diniz BS, Talib LL, Joaquim HP, De Paula VR, Gattaz WF, Forlenza OV. Platelet GSK3B activity in patients with late-life depression: marker of depressive episode severity and cognitive impairment?. World J Biol Psychiatry 2011; 12: 216-222
24. Karege F, Perroud N, Burkhardt S, Fernandez R, Ballmann E, La Harpe R, Malafosse A. Protein levels of β-catenin and activation state of glycogen synthase kinase-3β in major depression. A study with postmortem prefrontal cortex. J Affect Disord 2012; 136: 185-188
25. Karege F, Perroud N, Burkhardt S, Schwald M, Ballmann E, La Harpe R, Malafosse A. Alteration in kinase activity but not in protein levels of protein kinase B and glycogen synthase kinase-3β in ventral prefrontal cortex of depressed suicide victims. Biol Psychiatry 2007; 61: 240-245
26. Marksteiner J, Humpel C. Glycogen-synthase kinase-3β is decreased in peripheral blood mononuclear cells of patients with mild cognitive impairment. Exp Gerontol 2009; 44: 370-371
27. Pandey GN, Ren X, Rizavi HS, Dwivedi Y. Glycogen synthase kinase-3β in the platelets of patients with mood disorders: effect of treatment. J Psychiatr Res 2010; 44: 143-148
28. Li X, Liu M, Cai Z, Wang G. Regulation of glycogen synthase kinase-3 during bipolar mania treatment. Bipolar Disord 2010; 12: 741-752
29. Polter A, Beurel E, Yang S, Garner R, Song L, Miller CA, Sweatt JD, McMahon L, Bartolucci AA, Li X, Jope RS. Deficiency in the inhibitory serine-phosphorylation of glycogen synthase kinase-3 increases sensitivity to mood disturbances. Neuropsychopharmacology 2010; 35: 1761-1774
30. Joaquim HP, Talib LL, Forlenza OV, Diniz BS, Gattaz WF. Long-Term sertraline treatment increases expression and decreases phosphorylation of glycogen synthase kinase-3B in platelets of patients with late-life major depression. J Psychiatr Res 2012; 46: 1053-1058
31. Hye A, Kerr F, Archer N, Foy C, Poppe M, Brown R, Hamilton G, Powell J, Anderton B, Lovestone S. Glycogen synthase kinase-3 is increased in white cells early in Alzheimers disease. Neurosci Lett 2005; 373: 1-4
32. Hoehn KL, Hudachek SF, Summers SA, Florant GL. Seasonal, tissue-specific regulation of Akt/protein kinase B and glycogen synthase in hibernators. Am J Physiol Regul Integr Comp Physiol 2004; 286: R498-R504
33. Besing RC, Paul JR, Hablitz LM, Rogers CO, Johnson RL, Young ME, Gamble KL. Circadian rhythmicity of active GSK3 isoforms modulates molecular clock gene rhythms in the suprachiasmatic nucleus. J Biol Rhythms 2015; 30: 155-160
34. Wing JK, Babor T, Brugha T, Burke J, Cooper JE, Giel R, Jablenski A, Regier D, Sartorius N. SCAN: Schedules for Clinical Assessment in Neuropsychiatry. Arch Gen Psychiatry 1990; 47: 589-593
35. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62
36. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-389
37. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133: 429-435
38. Cheon Y, Park JY, Modi HR, Kim HW, Lee HJ, Chang L, Rao JS, Rapoport SI. Chronic olanzapine treatment decreases arachidonic acid turnover and prostaglandin E 2 concentration in rat brain. J Neurochem 2011; 119: 364-376
39. Kim HW, Rapoport SI, Rao JS. Altered arachidonic acid cascade enzymes in postmortem brain from bipolar disorder patients. Mol Psychiatry 2011; 16: 419-428
40. Wechsler D. Wechsler Adult Intelligence Scale-III. San Antonio, Psychological Corporation, 1997
41. Randolph C. RBANS Manual: Repeatable Battery for the Assessment of Neuropsychological Status. San Antonio, Psychological Corporation, 1998
42. War Department AGsO: Army Individual Test Battery: Manual of Directions and Scoring. Washington, War Department, Adjutant General's Office, 1944
43. Derogatis LR, Melisaratos N. The Brief Symptom Inventory: an introductory report. Psychol Med 1983; 13: 595-605
44. Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol 1988; 54: 1063-1070
45. Joaquim HP, Talib LL, Forlenza OV, Diniz BS, Gattaz WF. Long-Term sertraline treatment increases expression and decreases phosphorylation of glycogen synthase kinase-3B in platelets of patients with late-life major depression. J Psychiatr Res 2012; 46: 1053-1058
46. Patel S, Doble BW, MacAulay K, Sinclair EM, Drucker DJ, Woodgett JR. Tissue-specific role of glycogen synthase kinase 3β in glucose homeostasis and insulin action. Mol Cell Biol 2008; 28: 6314-6328
47. Kaladchibachi SA, Doble B, Anthopoulos N, Woodgett JR, Manoukian AS. Glycogen synthase kinase 3, circadian rhythms, and bipolar disorder: a molecular link in the therapeutic action of lithium. J Circadian Rhythms 2007; 5: 3
48. Atsma F, De Vegt F. The healthy donor effect: a matter of selection bias and confounding. Transfusion 2011; 51: 1883-1885
49. Gladkevich A, Kauffman HF, Korf J. Lymphocytes as a neural probe: potential for studying psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 559-576
50. Castri P, Iacovelli L, De Blasi A, Giubilei F, Moretti A, Tari Capone F, Nicoletti F, Orzi F. Reduced insulin-induced phosphatidylinositol-3-kinase activation in peripheral blood mononuclear leucocytes from patients with Alzheimer's disease. Eur J Neurosci 2007; 26: 2469-2472
51. Sullivan PF, Fan C, Perou CM. Evaluating the comparability of gene expression in blood and brain. Am J Med Genet B Neuropsychiatr Genet 2006; 141B: 261-268
52. Munkholm K, Weikop P, Kessing LV, Vinberg M. Elevated levels of IL-6 and IL-18 in manic and hypomanic states in rapid cycling bipolar disorder patients. Brain Behav Immun 2015; 43: 205-213
53. Munkholm K, Peijs L, Kessing LV, Vinberg M. Reduced mRNA expression of PTGDS in peripheral blood mononuclear cells of rapidcycling bipolar disorder patients compared with healthy control subjects. Int J Neuropsychopharmacol 2015; 18: pyu101
54. Munkholm K, Brauner JV, Kessing LV, Vinberg M. Cytokines in bipolar disorder vs. healthy control subjects: a systematic review and meta-Analysis. J Psychiatr Res 2013; 47: 1119-1133
55. Munkholm K, Vinberg M, Berk M, Kessing LV. State-related alterations of gene expression in bipolar disorder: a systematic review. Bipolar Disord 2012; 14: 684-696
56. Munkholm K, Pedersen BK, Kessing LV, Vinberg M. Elevated levels of plasma brain derived neurotrophic factor in rapid cycling bipolar disorder patients. Psychoneuroendocrinology 2014; 47: 199-211
57. Munkholm K, Poulsen HE, Kessing LV, Vinberg M. Elevated levels of urinary markers of oxidatively generated DNA and RNA damage in bipolar disorder. Bipolar Disord 2015; 17: 257-268
58. Goldstein BI, Young LT. Toward clinically applicable biomarkers in bipolar disorder: focus on BDNF, inflammatory markers, and endothelial function. Curr Psychiatry Rep 2013; 15: 425